Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5810224 | 0.91 | P2RX7 (0.63) | P2RX7HSD11B1KCNN4POLBHTT | |
| SCHEMBL5816902 | 0.82 | P2RX7 (0.67) | P2RX7HSD11B1IDO1TDO2KCNN4 | |
| SCHEMBL5802186 | 0.81 | P2RX7 (0.83) | P2RX7 | |
| SCHEMBL6360839 | 0.78 | P2RX7 (0.62) | P2RX7IDO1TDO2 | |
| SCHEMBL6361666 | 0.77 | P2RX7 (0.58) | P2RX7HSD11B1KCNN4 | |
| SCHEMBL6358346 | 0.76 | P2RX7 (0.62) | P2RX7HSD11B1POLBHTTL3MBTL1 | |
| SCHEMBL6362702 | 0.76 | HSD11B1 (0.58) | P2RX7HSD11B1KCNN4 | |
| SCHEMBL6362202 | 0.76 | P2RX7 (0.68) | P2RX7HSD11B1POLBHTTL3MBTL1 | |
| SCHEMBL6848952 | 0.74 | NPC1 (0.53) | P2RX7HSD11B1POLBHTTL3MBTL1 | |
| SCHEMBL5802163 | 0.73 | P2RX7 (0.67) | P2RX7HSD11B1IDO1TDO2KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | P2RX7 448/4885HSD11B1 511/4885IDO1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.